GE holding on to life-science operations

Jeffrey Immelt, GE’s chairman and CEO, has been busy reshaping the company so that it revolves more around heavy industry, but there appear to be no current plans to sell GE’s life-sciences business.

As reported by Bloomberg Business, GE is actually looking to grow that side of its business, which includes imaging, chromatography, cell-therapy tools, and more.

“It’s a fundamentally attractive industry with growth and we have a very strong competitive position,’’ said John Flannery, president and CEO of GE Healthcare, as quoted by Bloomberg Business. “We are certain this business grows faster inside of GE than it would grow outside.”

Click below for the full text from Bloomberg Business, which also goes on to summarize a lot of key information regarding GE’s continued transformation: 

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The all-in-one Omni Legend PET/CT scanner is now being manufactured in a new production facility in Waukesha, Wisconsin.